MX360045B - Combinaciones farmacéuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf. - Google Patents
Combinaciones farmacéuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.Info
- Publication number
- MX360045B MX360045B MX2015001122A MX2015001122A MX360045B MX 360045 B MX360045 B MX 360045B MX 2015001122 A MX2015001122 A MX 2015001122A MX 2015001122 A MX2015001122 A MX 2015001122A MX 360045 B MX360045 B MX 360045B
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitor
- cdk4
- raf
- pharmaceutical combinations
- combination
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000002062 proliferating effect Effects 0.000 abstract 2
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 abstract 1
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 abstract 1
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 abstract 1
- 101100381978 Mus musculus Braf gene Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una combinación farmacéutica que comprende: (a) un inhibidor de CDK4/6, (b) un inhibidor de B-Raf, y opcionalmente (c) un inhibidor de MEK 1/2; preparaciones combinadas y composiciones farmacéuticas de las mismas; los usos de esta combinación en el tratamiento de enfermedades proliferativas; y los métodos para el tratamiento de un sujeto que padezca de una enfermedad proliferativa, los cuales comprenden administrar una cantidad terapéuticamente eficaz de esta combinación.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261676134P | 2012-07-26 | 2012-07-26 | |
US201361830911P | 2013-06-04 | 2013-06-04 | |
PCT/US2013/051990 WO2014018725A1 (en) | 2012-07-26 | 2013-07-25 | Pharmaceutical combinations of a cdk4/6 inhibitor and a b-raf inhibitor |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015001122A MX2015001122A (es) | 2015-04-08 |
MX360045B true MX360045B (es) | 2018-10-19 |
Family
ID=48917729
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015001122A MX360045B (es) | 2012-07-26 | 2013-07-25 | Combinaciones farmacéuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf. |
Country Status (16)
Country | Link |
---|---|
US (1) | US9700557B2 (es) |
EP (1) | EP2877174B1 (es) |
JP (1) | JP6320379B2 (es) |
KR (1) | KR102113363B1 (es) |
CN (1) | CN104507474B (es) |
AR (1) | AR091876A1 (es) |
AU (1) | AU2013295771B2 (es) |
CA (1) | CA2874860C (es) |
ES (1) | ES2778059T3 (es) |
HK (1) | HK1210721A1 (es) |
IN (1) | IN2015DN00376A (es) |
JO (1) | JO3776B1 (es) |
MX (1) | MX360045B (es) |
RU (1) | RU2685250C2 (es) |
TW (1) | TWI599357B (es) |
WO (1) | WO2014018725A1 (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9867825B2 (en) * | 2012-12-20 | 2018-01-16 | Novartis Ag | Pharmaceutical combination comprising binimetinib |
WO2014130932A2 (en) * | 2013-02-25 | 2014-08-28 | Novartis Ag | Novel androgen receptor mutation |
MX2015013466A (es) * | 2013-03-21 | 2016-06-21 | Novartis Ag | Terapia de combinacion que comprende un inhibidor deb-raf y un segundo inhibidor. |
CN107205933A (zh) * | 2014-12-23 | 2017-09-26 | 米伦纽姆医药公司 | Raf抑制剂与aurora激酶抑制剂的组合 |
CN105753869B (zh) * | 2015-04-01 | 2018-09-25 | 苏州晶云药物科技有限公司 | 一种cdk抑制剂和mek抑制剂的共晶及其制备方法 |
WO2016155670A1 (zh) * | 2015-04-01 | 2016-10-06 | 苏州晶云药物科技有限公司 | 一种cdk抑制剂和mek抑制剂的共晶及其制备方法 |
JP2018526377A (ja) * | 2015-08-28 | 2018-09-13 | ノバルティス アーゲー | がんを治療するための、任意にpi3k阻害剤のbyl719を更に含む、cdk4/6阻害剤のlee011とmek1/2阻害剤トラメチニブの組み合わせ物 |
CN105732642B (zh) * | 2015-11-18 | 2018-09-25 | 苏州晶云药物科技有限公司 | 一种cdk抑制剂和mek抑制剂的共晶及其制备方法 |
SG11201810793XA (en) * | 2016-06-03 | 2018-12-28 | Giordano Caponigro | Pharmaceutical combinations |
EP3503923B1 (en) * | 2016-08-23 | 2023-10-04 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of hepatocellular carcinoma |
ES2974991T3 (es) | 2016-09-19 | 2024-07-02 | Novartis Ag | Combinaciones terapéuticas que comprenden un inhibidor de RAF y un inhibidor de ERK |
WO2018081211A1 (en) * | 2016-10-26 | 2018-05-03 | Li George Y | Deuterated 7-cyclopentyl-n, n-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7h-pyrrolo[2,3-d]pyrimdine-6-carboxamide |
US11395821B2 (en) | 2017-01-30 | 2022-07-26 | G1 Therapeutics, Inc. | Treatment of EGFR-driven cancer with fewer side effects |
KR102641827B1 (ko) * | 2017-05-02 | 2024-03-04 | 노파르티스 아게 | 병용 요법 |
MX2020007312A (es) | 2018-01-08 | 2021-01-08 | G1 Therapeutics Inc | Regimenes de dosificacion superior de g1t38. |
CN112334451A (zh) | 2018-02-15 | 2021-02-05 | 诺维逊生物股份有限公司 | 作为激酶抑制剂的杂环化合物 |
WO2019195959A1 (en) * | 2018-04-08 | 2019-10-17 | Cothera Biosciences, Inc. | Combination therapy for cancers with braf mutation |
US11633401B2 (en) * | 2018-07-06 | 2023-04-25 | Memorial Sloan Kettering Cancer Center | Combination therapy with MEK inhibitor and CDK4/6 inhibitor to treat pancreatic cancer |
AU2019407159A1 (en) * | 2018-12-20 | 2021-07-15 | Novartis Ag | Combination therapy with a Raf inhibitor and a CKD4/6 inhibitor for use in the treatment of cancer |
WO2021047573A1 (zh) * | 2019-09-11 | 2021-03-18 | 江苏恒瑞医药股份有限公司 | 一种mek抑制剂与cdk4/6抑制剂联合在制备治疗肿瘤的药物中的用途 |
WO2021229439A1 (en) * | 2020-05-12 | 2021-11-18 | Novartis Ag | Therapeutic combinations comprising a craf inhibitor |
WO2023230554A1 (en) | 2022-05-25 | 2023-11-30 | Pfizer Inc. | Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ535158A (en) * | 2002-03-13 | 2007-06-29 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as MEK inhibitors |
US7235537B2 (en) * | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
EP1740184A1 (en) * | 2004-03-30 | 2007-01-10 | Pfizer Products Incorporated | Combinations of signal transduction inhibitors |
MX2011000440A (es) | 2008-07-11 | 2011-02-24 | Novartis Ag | Combinacion de (a) un inhibidor de fosfoinositido 3-cinasa y (b) un modulador de la ruta de ras/raf/mek. |
KR101353857B1 (ko) * | 2008-08-22 | 2014-01-21 | 노파르티스 아게 | Cdk 억제제로서 피롤로피리미딘 화합물 |
AR077975A1 (es) * | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
ES2689177T3 (es) * | 2010-04-13 | 2018-11-08 | Novartis Ag | Combinación que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclina (CDK4/6) y un inhibidor de mTOR para tratar cáncer |
-
2013
- 2013-07-24 AR ARP130102621A patent/AR091876A1/es not_active Application Discontinuation
- 2013-07-25 IN IN376DEN2015 patent/IN2015DN00376A/en unknown
- 2013-07-25 ES ES13745540T patent/ES2778059T3/es active Active
- 2013-07-25 EP EP13745540.8A patent/EP2877174B1/en active Active
- 2013-07-25 AU AU2013295771A patent/AU2013295771B2/en active Active
- 2013-07-25 WO PCT/US2013/051990 patent/WO2014018725A1/en active Application Filing
- 2013-07-25 TW TW102126726A patent/TWI599357B/zh active
- 2013-07-25 JP JP2015524444A patent/JP6320379B2/ja active Active
- 2013-07-25 KR KR1020157001594A patent/KR102113363B1/ko active IP Right Grant
- 2013-07-25 US US14/414,998 patent/US9700557B2/en active Active
- 2013-07-25 RU RU2015106524A patent/RU2685250C2/ru active
- 2013-07-25 CN CN201380039725.5A patent/CN104507474B/zh active Active
- 2013-07-25 CA CA2874860A patent/CA2874860C/en active Active
- 2013-07-25 MX MX2015001122A patent/MX360045B/es active IP Right Grant
- 2013-07-25 JO JOP/2013/0223A patent/JO3776B1/ar active
-
2015
- 2015-11-27 HK HK15111684.1A patent/HK1210721A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
TWI599357B (zh) | 2017-09-21 |
JO3776B1 (ar) | 2021-01-31 |
MX2015001122A (es) | 2015-04-08 |
JP6320379B2 (ja) | 2018-05-09 |
US9700557B2 (en) | 2017-07-11 |
IN2015DN00376A (es) | 2015-06-12 |
US20150164897A1 (en) | 2015-06-18 |
RU2015106524A (ru) | 2016-09-20 |
AR091876A1 (es) | 2015-03-04 |
EP2877174B1 (en) | 2020-01-01 |
BR112014033118A8 (pt) | 2023-01-31 |
AU2013295771B2 (en) | 2016-08-11 |
KR20150036146A (ko) | 2015-04-07 |
CA2874860C (en) | 2020-06-23 |
ES2778059T3 (es) | 2020-08-07 |
WO2014018725A1 (en) | 2014-01-30 |
RU2685250C2 (ru) | 2019-04-17 |
AU2013295771A1 (en) | 2014-12-11 |
BR112014033118A2 (pt) | 2017-06-27 |
HK1210721A1 (en) | 2016-05-06 |
CA2874860A1 (en) | 2014-01-30 |
CN104507474B (zh) | 2018-01-02 |
CN104507474A (zh) | 2015-04-08 |
KR102113363B1 (ko) | 2020-05-21 |
JP2015523397A (ja) | 2015-08-13 |
EP2877174A1 (en) | 2015-06-03 |
TW201412316A (zh) | 2014-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX360045B (es) | Combinaciones farmacéuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf. | |
PH12015500246A1 (en) | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor | |
PH12015501067A1 (en) | Pyrrolopyrimidine compounds as kinase inhibitors | |
MX2020010412A (es) | Inhibidores de tirosina quinasa de bruton. | |
PH12016500575A1 (en) | Inhibitors of bruton`s tyrosine kinase | |
PH12015500940A1 (en) | Bruton`s tyrosine kinase inhibitors | |
MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
MX2014010590A (es) | Terapia de combinacion para trastornos proliferativos. | |
PH12014501815A1 (en) | Purinone compounds as kinase inhibitors | |
AU2011328009A8 (en) | Compounds and methods for treating pain | |
MX2013011908A (es) | Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank. | |
WO2015054619A8 (en) | Use of a pcsk9 inhibitor to treat hyperlipidemia | |
TW201613919A (en) | Inhibitors of Bruton's tyrosine kinase | |
MX2014001393A (es) | 3-(bifenil-3-il)-4-hidroxi-8-metoxi-1-azaespiro[4.5]dec-3-en-2-on as sustituidas. | |
PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
UA115250C2 (uk) | Фармацевтичні комбінації | |
MX368735B (es) | (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina. | |
TW201613926A (en) | Inhibitors of bruton's tyrosine kinase | |
WO2014170820A3 (en) | A pharmaceutical combination for treating tuberculosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |